Innovation in cardiovascular disease in Europe with focus on arrhythmias: current status, opportunities, roadblocks, and the role of multiple stakeholders

Journal article

The European Heart Rhythm Association (EHRA) held an Innovation Forum in February 2016, to consider issues around innovation. The objective of the forum was to extend the innovation debate outside of the narrow world of arrhythmia specialists and cardiology in general, and seek input from all stakeholders including regulators, strategists, technologists, industry, academia, health providers, medical societies, payers, and patients. Innovation is indispensable for a continuing improvement in health care, preferably at higher efficacy and lower costs. It requires people who have been trained in a good scientific environment, high-quality research for achieving ground breaking inventions and the certainty of return on innovation investments. In the context of cardiovascular disease, innovation can imply better risk assessment and stratification, device technology, drug development, and process design. Several areas of promising developments were identified as well as several roadblocks to innovation. To drive innovation forward all stakeholders need to play a significant role. In a globalized and extremely competitive world, the leading role of Europe in medical innovation can only be achieved through a combined and well-coordinated effort from all involved parties.

Authors: Prinzen, FW; Dagres, N; Bollmann, A; Arnar, DO; Bove, S

• Publication status: Published
• Peer review status: Peer reviewed
• Publisher: Oxford University Press
• Journal: EP Europace
• Volume: 20
• Issue: 5
• Pages: 733–738
• Publication date: 2017-06-12
• Acceptance date: 2017-03-14
• DOI: 10.1093/europace/eux095
• EISSN: 1532-2092
• ISSN: 1099-5129
• Pmid: 28605436
• Language: English
• Keywords: basic science; patents; devices; big data; innovation; clinical trial; computer models; personalized medicine; genetics; electrophysiology; reimbursement; arrhythmias